Relationship between aldosterone and the metabolic syndrome in patients with obstructive sleep apnea hypopnea syndrome: Effect of continuous positive airway pressure treatment

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Barceló, Antonia ^a,b,d   Piérola, Javier ^a,d   Esquinas, Cristina ^c   De La Peña, Mónica ^a,d   Arqué, Meritxell ^a,d   Alonso Fernández, Alberto ^a,d   Bauçà, Josep Miquel ^a,b   Robles, Juan ^a,b   Barceló, Bernardino ^a,b   Barbé, Ferran ^c,d  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^b Servei de Pneumologia ^*  (Spain)

^c HOSPITAL ARNAU DE VILANOVA   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; CHOLESTEROL; CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PLASMA RENIN ACTIVITY; POSITIVE END EXPIRATORY PRESSURE; POSITIVE END EXPIRATORY PRESSURE VENTILATOR; SLEEP DISORDERED BREATHING; THERAPY EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84905686184     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.-pone.0084362     Document Type: Article

References (38)

1. Lam JC, Ip MS (2007)An update on obstructive sleep apnea and the metabolic syndrome. Curr.Opin.Pulm.Med. 13: 484-489. (Pubitemid 47494196)
2. Bonsignore MR, Zito A (2008) Metabolic effects of the obstructive sleep apnea syndrome and cardiovascular risk. Arch.Physiol Biochem. 114: 255-260.
3. Levy P, Bonsignore MR, Eckel J (2009) Sleep, sleep-disordered breathing and metabolic consequences. Eur.Respir J. 34: 243-260.
4. Stewart PM (1999) Mineralocorticoid hypertension. Lancet. 353: 1341-1347.
5. Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, et al. (2004) Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N.Engl.J.Med. 351: 33-41.
6. Acelajado MC, Calhoun DA (2011) Aldosteronism and resistant hypertension. Int.J.Hypertens. 2011. 837817.
7. Briet M, Schiffrin EL (2011) The role of aldosterone in the metabolic syndrome. Curr.Hypertens.Rep. 13: 163-172.
8. Krug AW, Ehrhart-Bornstein M (2008) Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additional risk factor? Hypertension. 51: 1252-1258. (Pubitemid 351555932)
9. Lastra-Lastra G, Sowers JR, Restrepo-Erazo K, Manrique-Acevedo C, Lastra-Gonzalez G (2009) Role of aldosterone and angiotensin II in insulin resistance: an update. Clin.Endocrinol.(Oxf). 71: 1-6.
10. Kidambi S, Kotchen JM, Grim CE, Raff H, Mao J, et al. (2007) Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension. 49: 704-711.
11. Hannemann A, Meisinger C, Bidlingmaier M, Doring A, Thorand B, et al. (2011) Association of plasma aldosterone with the metabolic syndrome in two German populations. Eur.J.Endocrinol. 164: 751-758.
12. Bochud M, Nussberger J, Bovet P, Maillard MR, Elston RC, et al. (2006) Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension. 48: 239-245. (Pubitemid 44309818)
13. Fallo F, Veglio F, Bertello C, Sonino N, Della MP, et al. (2006) Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J.Clin.-Endocrinol.Metab. 91: 454-459. (Pubitemid 43236909)
14. Ingelsson E, Pencina MJ, Tofler GH, Benjamin EJ, Lanier KJ, et al. (2007) Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation. 116: 984-992. (Pubitemid 47329563)
15. Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, Cofield SS, Harding SM, et al. (2007) Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest. 131: 453-459.
16. Dudenbostel T, Calhoun DA (2012) Resistant hypertension, obstructive sleep apnoea and aldosterone. J.Hum.Hypertens. 26: 281-287.
17. Gonzaga CC, Gaddam KK, Ahmed MI, Pimenta E, Thomas SJ, et al. (2010) Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. J.Clin.Sleep Med. 6: 363-368.
18. Sim JJ, Yan EH, Liu IL, Rasgon SA, Kalantar-Zadeh K, et al. (2011) Positive relationship of sleep apnea to hyperaldosteronism in an ethnically diverse population. J.Hypertens. 29: 1553-1559.
19. Goodfriend TL (2008) Obesity, sleep apnea, aldosterone, and hypertension. Curr.Hypertens.Rep. 10: 222-226.
20. Pimenta E, Calhoun DA, Oparil S (2009) Sleep apnea, aldosterone, and resistant hypertension. Prog.Cardiovasc.Dis. 51: 371-380.
21. Gaddam K, Pimenta E, Thomas SJ, Cofield SS, Oparil S, et al. (2010) Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J.Hum.Hypertens. 24: 532-537.
22. Saarelainen S, Hasan J, Siitonen S, Seppala E (1996) Effect of nasal CPAP treatment on plasma volume, aldosterone and 24-h blood pressure in obstructive sleep apnoea. J.Sleep Res. 5: 181-185. (Pubitemid 26380247)
23. Svatikova A, Olson LJ, Wolk R, Phillips BG, Adachi T, et al.(2009) Obstructive sleep apnea and aldosterone. Sleep 32: 1589-1592.
24. Umemura S, Nyui N, Tamura K, Hibi K, Yamaguchi S, et al. (1997) Plasma angiotensinogen concentrations in obese patients. Am.J.Hypertens. 1997. 10: 629-633. (Pubitemid 27293478)
25. Egan BM, Stepniakowski K and Goodfrien TL (1994) Renin and aldosterone are higher and the hyperinsulinemic effect of salt restriction greater in subjects with risk factors clustering. Am.J.Hypertens. 7: 886-893. (Pubitemid 24349058)
26. Cooper R, McFarlane-Anderson N, Bennett FI, Wilks R, Puras A, et al.(1997) ACE, angiotensinogen and obesity: a potential pathway leading to hypertension. J.Hum.Hypertens. 11: 107-111. (Pubitemid 27202252)
27. Goodfriend TL, Kelley DE, Goodpaster BH, Winters SJ (1999) Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes.Res. 7: 355-362. (Pubitemid 129710596)
28. Vaz M, Jennings G, Turner A, Cox H, Lambert G, et al. (1997) Regional sympathetic nervous activity and oxygen consumption in obese normotensive human subjects. Circulation. 96: 3423-3429. (Pubitemid 27513415)
29. Thethi T, Kamiyama M, Kobori H (2012) The link between the renin-angiotensin-aldosterone system and renal injury in obesity and the metabolic syndrome. Curr.Hypertens.Rep. 14: 160-169.
30. Goodfriend TL, Egan BM, Kelley DE (1999) Plasma aldosterone, plasma lipoproteins, obesity and insulin resistance in humans. Prostaglandins Leukot. Essent.Fatty Acids. 60: 401-405. (Pubitemid 29401800)
31. Marzolla V, Armani A, Zennaro MC, Cinti F, Mammi C, et al. (2012) The role of the mineralocorticoid receptor in adipocyte biology and fat metabolism. Mol.Cell Endocrinol. 350: 281-288.
32. Hall JE (2003) The kidney, hypertension, and obesity. Hypertension. 41: 625-633.
33. Briet M, Schiffrin EL (2011) The role of aldosterone in the metabolic syndrome. Curr.Hypertens.Rep. 13: 163-172.
34. Stiefel P, Vallejo-Vaz AJ, Garcia MS, Villar J (2011) Role of the Renin-Angiotensin system and aldosterone on cardiometabolic syndrome. Int.J.Hypertens. 2011. 685238.
35. Yvan-Charvet L and Quignard-Boulange A (2011) Role of adipose tissue renin-angiotensin system in metabolic and inflammatory diseases associated with obesity. Kidney Int. 79: 162-168.
36. de Kloet AD, Krause EG, Woods SC (2010) The renin angiotensin system and the metabolic syndrome. Physiol Behav. 100: 525-534.
37. Strazzullo P, Galletti F (2004) Impact of the renin-angiotensin system on lipid and carbohydrate metabolism. Curr.Opin.Nephrol.Hypertens. 13: 325-332. (Pubitemid 38582306)
38. Giordani I, Malandrucco I, Picconi F, Longo S, Di Flaviani A, et al. (2013). Preliminary evidence that obese patients with obstructive sleep apnea/hypopnea syndrome are refractory to the acute beneficial metabolic effects of a very low calorie diet.Acta Diabetol. 50: 639-643.